Urethral diverticulum carcinoma management: a case report and review of the literature Authors: Xuefan Yang, Yulin Lai, Dihao Deng, Wenqi Jiang, Qiong Deng, Zhu Wang, Hui Liang Published: 2026 ABSTRACT AbstractBackgroundFemale urethral diverticulum carcinoma (UDC) is an exceptionally rare malignancy within the female urogenital system. The reported incidence of urethral diverticulum in females ranges from 0.02% to 6%, with malignant transformation occurring in an even smaller subset of cases. The extreme rarity of this condition has significantly constrained both basic research into its pathogenesis and the accumulation of clinical experience in its management.Case presentationA 46-year-old Han Chinese female presented with a 2-year history of increased urinary frequency, urgency, and dysuria. Pelvic MRI with contrast enhancement revealed a well-defined neoplastic lesion measuring 4.9 × 4.9 × 5.1 cm surrounding the urethra. Urethroscopic examination and radiological evaluation showed a urethral diverticulum suspicious for malignancy. Histopathological analysis of the biopsy specimen indicated papillary carcinoma. The patient underwent anterior pelvic exenteration, ileal conduit urinary diversion, and vaginal reconstruction. Postoperative pathological examination suggested high-grade urothelial carcinoma with glandular differentiation in the urethra, with evidence of invasion into the muscular layer of the bladder wall.ConclusionsUDC presents significant diagnostic challenges due to its nonspecific clinical manifestations and frequent delays in diagnosis, underscoring the importance of comprehensive physical examinations, including meticulous vaginal palpation, and advanced diagnostic procedures, such as cystoscopy with biopsy. The optimal treatment paradigm remains elusive, emphasizing the critical need for further clinical research, enhanced international collaboration, and the establishment of standardized treatment protocols to improve therapeutic outcomes for this rare and clinically challenging disease entity.Keywords: Urethral diverticulum carcinoma, Urethral diverticulum, Case report, Adenocarcinoma, Squamous cell cancer Background The annual incidence rate of primary urethral carcinoma among European women is 0.6 per million [1], while it is estimated that female patients developing a urethral diverticulum (UD) range from 0.02% to 6% [2]. Cacinorma arising from a female urethral diverticulum (UDC) is even rarer. Due to its rarity, the significant nonuniformity in its management in literature makes great challenges in its clinical diagnosis and treatment. The etiology of urethral diverticulum carcinoma remains unclear. Several studies suggest that female UDC is predominantly adenocarcinoma, assumed to arise from the proximal part of the para-urethral duct [3, 4]. The clinical manifestation of UDC is typically characterized by a lack of specificity. The presence of atypical symptoms poses a significant hurdle in arriving at a definitive diagnosis, often resulting in its misidentification as a urinary tract infection (UTI) [5]. According to EAU guidelines, UDC does not have a distinct clinical staging system and is currently classified using the staging criteria for primary urethral cancer [6]. However, because urethral diverticula lack inherent periurethral muscles, the T2 staging for urethral carcinoma is not applicable to urethral diverticulum carcinoma [6]. The incomplete applicability of clinical staging for urethral carcinoma to urethral diverticulum carcinoma poses significant challenges for its diagnosis, treatment, and research. In the present study, we report a case of female urethral diverticulum carcinoma, and comprehensively review the literature, summarizing the predominant histological types of female urethral diverticulum carcinoma, as well as its treatments and outcomes, to provide novel insights into the management of such a rare female disease. Case presentation The patient, a Han Chinese female in her mild 40 s, was admitted in November 2021 for the removal of uterine fibroids via laparoscopic myomectomy. An MR scan with contrast revealed a cystic lesion on the anterior vaginal wall (approximately 2.1*1.6 cm) (Fig. 1A, B), and regular follow-ups were recommended by the gynecology department. MRI findings of a vaginal wall lesion demonstrating interval change. A, B November 2021 pelvic MRI: cystic lesion in the anterior vaginal wall. A Sagittal T2-weighted image. B Axial T2-weighted image. Imaging impression: benign-appearing cystic lesion; C, D December 2023 pelvic MRI: interval development of a periurethral mass. C Sagittal T2-weighted image. D Axial T2-weighted image. Imaging findings: suggest malignant transformation within a Skene's gland cyst/urethral diverticulum, suspicious for diverticular carcinoma, with possible left inguinal lymph node metastasis One year ago, the patient started experiencing unexplained urinary frequency, urgency, and dysuria, which worsened over 2 months. There was no gross hematuria, nocturia, acute urinary retention, or significant pain in the pubic region or during intercourse. Despite multiple courses of anti-infective treatment, the symptoms persisted. On revisiting the outpatient department in December, 2023, a pelvic CT scan with contrast revealed a hypervascular mass on the anterior vaginal wall, measuring approximately 2.0 × 1.5 cm, with an increase in solid components compared to the previous scan. Left inguinal lymph node enlargement was noted, suggesting a malignant lesion (Fig. 1C, D). The patient reported no significant weight changes, but mentioned prolonged menstrual cycles and constipation. She had no other underlying diseases or infectious conditions, and there was no relevant family history. Physical examination via vaginal touch revealed a 2.0 by 1.0 cm mass on the anterior vaginal wall, soft in texture, with milky urethral discharge upon pressure, without significant tenderness, ill-defined margins, and poor mobility. A swollen lymph node was palpable in the left inguinal region, with clear boundaries and no significant tenderness; the right lymph nodes were appeared normal. Upon admission, further investigations were conducted. Urinalysis showed a small trace of occult blood, and the complete blood count revealed a slight increase in neutrophils and a decrease in hemoglobin to 99 g/L. Routine biochemical tests showed a decrease in albumin to 27.8 g/L. Tumor markers, including CA125, CA15-3, and CA19-9, were elevated to 2–3 times the normal values. Pelvic MR with contrast indicated a space-occupying lesion around the urethra, suggesting a Skene’s gland cyst/urethral diverticulum with malignant transformation and possible urethral carcinoma, with suspicious left inguinal lymph node metastasis. No significant abnormalities were found in other blood biochemical tests. Cystoscopy, urethral mass biopsy, and left inguinal lymph node excision were performed. Intraoperatively, multiple enlarged left inguinal lymph nodes were completely removed. Cystoscopy revealed significant protrusion in the trigone area of the bladder, with both ureteral orifices pushed posteriorly and indistinct. The bladder showed multiple trabeculations and small compartments, with no significant neoplasms on the bladder walls. Upon withdrawing the cystoscope from the urethra, a fistula was observed approximately 5 mm from the external urethral orifice, with a large amount of curd-like content extruding from the fistula when the anterior vaginal wall was compressed. After the procedure, two biopsies were taken from the mass on either side near the vaginal wall. Postoperative pathology reported papillary carcinoma tissue in the urethral mass content, and the enlarged lymph nodes showed inflammatory hyperplasia. A whole-body CT scan showed no evidence of metastasis to other sites.The immunohistochemical examination suggested a diagnosis of urothelial carcinoma, evidenced by positive staining for CK-pan, P63, GATA3, PAX-8, S100-P, CK7, β-catenin (membranous), and Ki-67 (with an approximate nuclear proliferation rate of 40%). CD44 and CEA exhibited partial positivity, while CK20, EMA, WT-1, PR, ER, and P40 were negative. Representative images are provided in Fig. 2. Histopathological analysis of the mass. A Hematoxylin and Eosin (H&E) staining; B CD44 staining; C PAX-8 staining; D S100-P staining. Pathological examination revealed urothelial carcinoma, evidenced by the presence of a small amount of atypical epithelium scattered within abundant necrotic material in the urethral mass. Immunohistochemical staining showed CD44 (focally positive), PAX-8 (positive), and S100P (positive). Scale bars: 1.25 mm for the left panel; 100 μm for the right panel After a definitive diagnosis, the patient underwent an anterior pelvic exenteration (including hysterectomy, bilateral salpingo-oophorectomy, cystectomy, urethrectomy, and anterior vaginal wall resection) and ileal conduit urinary diversion with vaginal reconstruction. The procedure was divided into abdominal and perineal surgical teams. The abdominal team noted a smooth bladder surface without abnormal nodules or protrusions. After mobilizing both ureters through the lateral peritoneum and ensuring their normal course without significant dilation or tumor invasion, the vaginal posterior wall was mobilized with difficulty due to severe adhesions, leading to a conversion to open laparotomy. Meanwhile, the perineal team performed a circumferential incision around the labium minus, dissecting and ligating the posterior labial vessels and opening the vaginal sidewalls to meet the abdominal team’s incision. The anterior pelvic organs and external genitalia were completely separated from the pelvic wall, and the specimen was removed through the perineal incision. The proximal free edge of the residual vaginal wall was everted and sutured to form a short vaginal canal, and the distal end was sutured to the perineal skin margins. The rectum was checked for injury, and hemostasis was ensured. A 15 cm segment of the terminal ileum with intact blood supply was used as the conduit (Bricker bladder), and both ureters were implanted with F5 single “J” stents into the antimesenteric wall of the free ileal segment. The ileal segment’s distal end was brought to the right lower abdominal wall for a circular skin stoma. The abdominal and pelvic cavities were thoroughly irrigated with distilled water. Once hemostasis was confirmed and no active bleeding was detected, a single drainage tube was strategically positioned, and the abdominal incision was meticulously closed in a layered fashion. Postoperative pathology revealed high-grade urothelial carcinoma with adenoid differentiation, measuring approximately 5.0 × 4.0 × 4.0 cm, invading the lamina propria of the bladder wall without clear neural or vascular invasion. The urethral margins and bilateral ureteral margins were free of cancer invasion. The patient recovered well and was discharged, with subsequent radiotherapy planned at the oncology department. At the most recent follow-up evaluation in January 2025, surveillance imaging and clinical assessment confirmed no evidence of disease recurrence. Conclusions and discussion UDC is a very rare phenomenon, with fewer than 130 reported cases in the current literature [5, 7]. Although UDC shares similar clinical manifestations with urethral carcinoma, they differ in tumor origin, predilection sites, and pathological types. UDC commonly occurs in the middle and distal urethra, aligning with typical urethral diverticula locations. Studies suggest that the prevalence of adenocarcinoma in urethral diverticulum carcinoma may relate to its origin from periurethral glands [3]. Research indicates that acquired urethral diverticula may form due to chronic obstruction or recurrent inflammation of periurethral glands, leading to glandular rupture and opening into the urethra [8]. Consequently, the formation of urethral diverticulum carcinoma might be associated with repeated infections of the periurethral glands. Findings from case reports of urethral diverticulum carcinoma during surgery [9, 10] have shown that incising the anterior vaginal wall exposed a large amount of pus within the diverticulum, partially supporting this hypothesis. The American Urological Association (AUA) provides guidelines for urethral adenocarcinoma diagnosis and treatment. However, strong clinical suspicion based on symptoms is needed to initiate timely diagnostic evaluation [11]. Thus, recognizing the typical clinical symptoms of this disease is critical in contemporary urological practice. It is reported that urethral bleeding or hematuria is the most frequently-occurring symptom, present in 55% of all patients. Subsequently, 16% of patients experience urethral obstruction/voiding dysfunction, 13% have a urethral/introital mass, 13% have UTIs, and 6% have localized pain [7, 12]. Hematuria is a common manifestation, which can range from grossly visible blood in the urine to microscopic hematuria (MH) only detected by laboratory tests. The differential diagnosis of hematuria covers multiple causes: physiological, pharmacological, false hematuria and urological pathologies, being fundamental in its study to assess the possible malignant neoplastic causes [13]. In general, after anamnesis, physical examination, study of urinary sediment, and laboratory analysis to determine renal function, ultrasound allows doctors to confirm or rule out a large number of processes related to the etiology of hematuria: cysts and kidney masses, renal lithiasis, nephrocalcinosis, benign prostatic hyperplasia, polyps or vesical masses. However, to establish a firm diagnosis of UDC, future efforts are needed to ensure appropriate urologic referral and optimize initial diagnostic strategies for patients with hematuria [13–15]. Urethral obstruction/voiding dysfunction is the second most common symptom of UDC, including slow urine flow, a thin stream, and dribbling, often occurs due to the obstruction of the urethra by the cancerous growth [16]. Frequent urination and urinary urgency are also frequently reported symptoms, as the cancer may irritate the urethra or bladder neck, increasing bladder sensitivity [17]. These atypical symptoms make definitive diagnosis very challenging, often leading to misdiagnosis as a urinary tract infection [5, 17–19]. Urethral pain during urination is another symptom, caused by the invasion of surrounding tissues or nerves by the cancer tissue [20, 21]. In addition, patients may notice an abnormal urethral mass or induration. Abnormal urethral discharge, such as purulent or bloody discharge, can be present due to cancer-related necrosis and infection. Inguinal lymph node enlargement may occur if the cancer has metastasized. Diagnostic methods for urethral diverticulum carcinoma typically include enhanced CT of the urinary system, pelvic MRI, and cystoscopy examination. Most urethral diverticulum carcinomas can be detected through cystoscopy, which reveals the opening of the diverticulum in the urethra and allows visualization of the tumor within the diverticulum [22]. Subsequently, a biopsy should be conducted for pathological analysis to confirm the diagnosis [23]. In addition, vaginal palpation during physical examination is crucial. It enables the accurate assessment of the mass's size and texture, allows for the observation of whether pressing on the mass causes discharge from the urethra, and palpation of the inguinal lymph nodes to evaluate for enlargement [24, 25]. In clinical practice, it has been observed that conducting a T2-weighted thin-slice post-void pelvic MRI is instrumental in detecting the presence of a urethral diverticulum. Furthermore, if the patient’s medical history, physical examination findings, or MRI results raise suspicion for the presence of cancer, it is imperative to promptly carry out an urgent urethral diverticulectomy. This surgical procedure serves as a definitive means of obtaining an “excision biopsy”, thereby facilitating accurate diagnosis and subsequent appropriate management [7]. The predominant pathology of UDC is adenocarcinoma (75%), followed by transitional cell carcinoma (TCC, 15%) and squamous cell carcinoma (SCC, 10%) [7, 16–18]. Adenocarcinoma is the most common histological type of urethral diverticulum cancer and originates from glandular cells within the urethral diverticulum [5, 26–30]. Microscopically, it shows a glandular structure with cancer cells arranged in gland-like patterns [31]. Transitional cell carcinoma, also known as urothelial carcinoma, stems from the transitional epithelial cells of the urethral mucosa. Its growth pattern can be papillary or invasive [7, 10, 32]. Urothelial carcinomas can be aggressive, particularly high-grade tumors, and may metastasize to regional lymph nodes or distant sites. Squamous cell carcinoma results from the malignant transformation of squamous epithelial cells of the urethral mucosa. It is characterized by features, such as intercellular bridges and keratin pearl formation [33, 34]. In contrast, the common pathological type of urethral carcinoma is squamous cell carcinoma, followed by adenocarcinoma and transitional cell carcinoma, indicating a different origin for urethral carcinoma and urethral diverticulum carcinoma. The histological type of UDC is a critical factor in determining the prognosis and guiding treatment. Adenocarcinoma is the most common type, but transitional cell carcinoma, squamous cell carcinoma, clear cell carcinoma and other rare types can also occur [35–38]. Accurate histological diagnosis, often supplemented by immunohistochemical staining, is essential for appropriate management. For instance, GATA3 is a highly sensitive and specific marker for urothelial carcinoma (UC), and can effectively aid in distinguishing UC from other genitourinary malignancies and metastatic tumors originating from the kidney or prostate [39–41]. 82% of urothelial carcinomas stained intensively positive for CK7 [42]. In addition, S100-P, also known as placental S100, is a member of the S100 protein family and is recognized as a promising immunohistochemical marker for supporting the diagnosis of urothelial differentiation [43]. CD44, a cell surface adhesion molecule mediating cell–cell and cell–matrix interactions, demonstrated positive expression in 87% of bladder urothelial carcinoma cases [44]. Paired box protein 8 (PAX-8) is a highly sensitive marker for specific types of epithelial tumors. In a recent study, PAX-8 immunohistochemical expression was detected in 56% of analyzed urothelial carcinoma cases, with staining intensity ranging from moderate to strong [45]. Conversely, CDX-2 and CK20 are markers commonly associated with gastrointestinal (GI) adenocarcinomas, particularly those originating in the colorectal region [46], which were negatively expressed in the present case. P40 exhibits high specificity for urothelial carcinoma (UC), and its expression demonstrates significant heterogeneity within UC specimens. Therefore, a negative p40 immunostaining cannot definitively exclude UC diagnosis, especially in tumors exhibiting poor differentiation or those accompanied by aggressive phenotypic evolution leading to P40 expression loss [47]. Collectively, immunohistochemical profiling of these characteristic biomarkers facilitates reliable diagnostic confirmation. Given the rarity of these tumors, treatment often follows principles used for similar cancers in other parts of the urinary tract, with surgery, radiation, and chemotherapy being the mainstay of treatment depending on the stage and histological type. According to the National Comprehensive Cancer Network (NCCN) guidelines, standard management for T2 urethral carcinoma typically involves transurethral resection followed by either cystourethrectomy or anterior pelvic exenteration. However, the optimal therapeutic approach for carcinoma arising within a urethral diverticulum (UD) remains undefined due to anatomical considerations and limited evidence [48]. The treatment for urethral diverticulum carcinoma varies depending on the histological type, stage, and presence of metastasis, with surgical removal combined with radiotherapy and chemotherapy being common approaches [5, 7]. Distal urethral diverticulum carcinoma and smaller urethral diverticulum carcinomas may be considered for local excision, although local recurrence rates are higher after such procedures [9]. This is the most common surgical approach for localized UDC. It involves the excision of the diverticulum and is often combined with other procedures such as Martius flap interposition to reinforce the repair and prevent complications like urethrovaginal fistula. In cases where the cancer is more extensive, a partial or complete urethrectomy may be performed, sometimes with pelvic or inguinal lymph node dissection. Some researchers propose anterior pelvic exenteration as the primary treatment for urethral diverticulum carcinoma [12, 16]. This radical surgery involves the removal of the bladder, urethra, anterior vaginal wall, uterus, and pelvic lymph nodes. It is typically reserved for advanced or high-grade tumors. In some cases, this is combined with neoadjuvant or adjuvant chemotherapy/radiotherapy [7, 29]. For advanced or aggressive tumors, a combination of surgery, radiation, and chemotherapy is often employed. This approach is tailored to the individual patient based on the stage and histological type of the cancer [7, 12, 49, 50]. Patients with adenocarcinoma generally have better outcomes than those with SCC. The 5-year survival rate for adenocarcinoma is around 72%, while for SCC, it is significantly lower at 25%. Recurrence rates are high, particularly for SCC, and close follow-up is essential [7, 12, 17]. The treatment of UDC requires a multidisciplinary approach, often involving a combination of surgery, radiation, and chemotherapy. Surgical excision remains the cornerstone of treatment, with adjuvant therapies used to improve outcomes. However, due to the rarity of the condition, there is a need for more standardized treatment protocols and international registries to better understand and manage this rare malignancy. Conclusion In summary, UDC is an exceptionally rare and complex malignancy of the female urinary system, often linked to urethral diverticula. Its nonspecific symptoms and delayed diagnosis pose significant challenges, necessitating thorough physical examinations, including vaginal palpation, and diagnostic procedures such as cystoscopy with biopsy. Radical surgery, particularly anterior pelvic exenteration, is recommended as the primary treatment, supplemented by postoperative radiotherapy and chemotherapy, especially for aggressive histological types like SCC, high-grade adenocarcinoma, or TCC. Despite moderate survival rates, optimal treatment strategies remain unclear, highlighting the need for further research, international collaboration, and standardized treatment protocols to improve outcomes for this rare and challenging disease. Acknowledgements Not applicable. Abbreviations Urethral diverticulum Urethral diverticulum carcinoma Squamous cell carcinoma Urinary tract infection Microscopic hematuria Transitional cell carcinoma Author contributions XY and DD composed the manuscript and literature review, had the acquisition, analysis, and interpretation of data for the work; YL, WJ and QD provided figures and pathology review; ZW and HL conceived and designed the study and supervised the research. All authors read and approved the final manuscript. Funding This study was supported by the Science and Technology Innovation Fund of Longhua Shenzhen (11501A20240704F5EB6FF), and Medical research project of Shenzhen Longhua Medical Association (2023LHMA01 and 2023LHMA28). Availability of data and materials Not applicable. Declarations Ethics approval and consent to participate This study has been approved by the Medical Ethics Committee of the People's Hospital of Longhua Shenzhen (No.[2024]-031A). Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interest The authors declare that they have no competing interest. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xuefan Yang, Yulin Lai, Dihao Deng and Wenqi Jiang contributed equally to this work. Contributor Information Zhu Wang, Email: wangzhu@smu.edu.cn. Hui Liang, Email: lianghui8689@smu.edu.cn. References Associated Data Data Availability Statement Not applicable.